GO:1904328 regulation of myofibroblast contraction: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1904328 (regulation of myofibroblast contraction) is a biological process that modulates the frequency, rate or extent of myofibroblast contraction, a key driver of wound closure and pathological fibrosis.
• Myofibroblast contraction is mechanically regulated by extracellular matrix (ECM) stiffness, transforming growth factor-beta (TGF-beta), and RhoA/ROCK signaling, which together control alpha-smooth muscle actin (ACTA2) stress fiber assembly.
• Calcium signaling, including TRPV4-mediated Ca2+ influx, regulates RhoA activity and myofibroblast contractility, linking mechanical cues to intracellular contraction machinery.
• Dysregulated myofibroblast contraction contributes to fibrosis in the heart, skin, lung, and vasculature, making this process a therapeutic target for antifibrotic strategies.
• Key genes involved include ACTA2, TGFB1, RhoA, ROCK1/2, SMAD7, COL5A1, and TRPV4, which can be studied using CRISPR knockout, point mutation, knock-in, and overexpression models.
• EDITGENE provides CRISPR-based cell model services and library screening to dissect the genetic regulation of myofibroblast contraction for fibrosis and cardiovascular research.
Description
Myofibroblasts are specialized contractile cells that emerge during tissue repair and are characterized by the expression of alpha-smooth muscle actin (ACTA2) and the formation of contractile stress fibers. The process of myofibroblast contraction is essential for wound closure and tissue remodeling, but when persistently activated, it drives pathological fibrosis in multiple organs. GO:1904328, regulation of myofibroblast contraction, encompasses any process that modulates the frequency, rate or extent of this contraction, integrating mechanical, chemical, and genetic signals. Understanding how myofibroblast contraction is regulated is critical for developing therapies that promote normal wound healing while preventing fibrosis and organ failure. This article synthesizes current knowledge from QuickGO and peer-reviewed literature to provide a research-grade overview of the mechanisms, genes, and experimental models relevant to GO:1904328.
regulation of myofibroblast contraction At A Glance
| GO ID | GO:1904328 |
|---|---|
| GO term | regulation of myofibroblast contraction |
| Ontology | biological_process |
| Synonym | regulation of MFB contraction; regulation of MF contraction |
| Major function | Modulates the frequency, rate or extent of myofibroblast contraction, influencing wound healing and fibrosis. |
| Key regulators | TGF-beta, RhoA/ROCK, calcium signaling, mechanical stiffness. |
| Associated diseases | Tissue fibrosis, heart failure, hypertension, scar formation. |
| Research methods | CRISPR knockout/knock-in, live-cell imaging, traction force microscopy, RNA-seq. |
What Is GO:1904328?
GO:1904328 (regulation of myofibroblast contraction) is defined as any process that modulates the frequency, rate or extent of myofibroblast contraction. In other words, it includes all molecular and cellular events that control how often, how fast, or how strongly myofibroblasts contract. This regulation can occur through changes in calcium signaling, RhoA/ROCK pathway activity, actin-myosin cytoskeletal dynamics, and mechanical feedback from the extracellular matrix.
Why Is regulation of myofibroblast contraction Important in Cell Biology?
Regulation of myofibroblast contraction is central to both normal tissue repair and the progression of fibrotic diseases. Myofibroblasts generate contractile forces that close wounds, but persistent contraction leads to stiff scar tissue, organ dysfunction, and failure. In the heart, myofibroblast contraction after myocardial infarction contributes to adverse remodeling and heart failure. In the vasculature, myofibroblast-like cells influence atherosclerosis and hypertension. Therefore, understanding GO:1904328 provides a foundation for therapeutic strategies that target myofibroblast contractility to treat fibrosis, cardiovascular disease, and other conditions.
• Myofibroblast contraction is essential for wound closure and tissue repair.
• Dysregulated contraction drives fibrosis in heart, skin, lung, and kidney.
• Mechanical stiffness of the ECM promotes myofibroblast phenoconversion and contraction.
• TGF-beta signaling is a master regulator of myofibroblast contraction and fibrosis.
• RhoA/ROCK and calcium signaling are key intracellular pathways controlling contractility.
• Type V collagen in scar tissue regulates scar size after heart injury.
• Vascular smooth muscle cell phenotypic switching contributes to atherosclerosis.
• Targeting myofibroblast contraction is a promising antifibrotic strategy.
• CRISPR-based models enable causal testing of candidate genes in contraction regulation.
• GO:1904328 provides a framework for annotating genes involved in contractile regulation.
What Happens During regulation of myofibroblast contraction?
Initiation by Mechanical and Chemical Cues
In simple terms: Myofibroblasts start contracting when they sense a stiff environment or receive chemical signals like TGF-beta.
Myofibroblast contraction is initiated by mechanical cues from the extracellular matrix (ECM) and chemical signals such as TGF-beta. Increased ECM stiffness promotes the activation of latent TGF-beta and the expression of alpha-smooth muscle actin (ACTA2), leading to stress fiber formation. TGF-beta signaling through SMAD proteins further drives the myofibroblast phenotype and contractile machinery. These cues converge on RhoA activation, which is a key switch for contractility.
Calcium Signaling and RhoA/ROCK Activation
In simple terms: Calcium enters the cell and activates RhoA, which then turns on ROCK to promote contraction.
Calcium signaling plays a central role in regulating myofibroblast contraction. TRPV4-mediated calcium influx activates RhoA by modulating RhoGDI1, leading to ROCK activation and increased contractility. Calcium also regulates myosin light chain kinase (MLCK) and myosin light chain phosphatase (MLCP), controlling the phosphorylation state of myosin light chain (MLC) and thus actin-myosin cross-bridge cycling. This calcium-RhoA-ROCK axis is a major node in GO:1904328.
Actin-Myosin Cytoskeleton Assembly and Force Generation
In simple terms: The cell builds a contractile machine made of actin and myosin fibers that pull on the matrix.
Once activated, RhoA/ROCK signaling promotes the assembly of actin stress fibers and the formation of focal adhesions. ACTA2 is incorporated into stress fibers, and myosin II generates contractile force through ATP-dependent cross-bridge cycling. This force is transmitted to the ECM via integrins, leading to matrix remodeling and further mechanical feedback. The regulation of this assembly process is a core component of GO:1904328.
Mechanical Feedback and Phenoconversion
In simple terms: The stiff scar tissue makes the myofibroblast even more contractile, creating a vicious cycle.
Myofibroblast contraction increases tissue stiffness, which in turn promotes further myofibroblast phenoconversion and contraction, creating a positive feedback loop. This mechanical feedback is mediated by mechanosensitive pathways including YAP/TAZ and TGF-beta activation. In the heart, type V collagen in scar tissue regulates scar size and mechanical properties, influencing myofibroblast contraction. This feedback loop is a key aspect of the regulation of myofibroblast contraction.
Resolution and Therapeutic Targeting
In simple terms: In normal healing, contraction stops; in fibrosis, it continues, so drugs are being developed to stop it.
In normal wound healing, myofibroblasts undergo apoptosis or de-differentiation after tissue repair is complete, terminating contraction. In pathological fibrosis, myofibroblasts persist, and contraction continues, leading to organ dysfunction. Pharmacological regulation of myofibroblast contraction, such as targeting RhoA/ROCK or calcium channels, is being explored as an antifibrotic strategy. Smad7 induction in fibroblasts protects against pressure-overload heart remodeling, highlighting endogenous negative regulation.
Key Genes Involved in GO:1904328 regulation of myofibroblast contraction
The following genes and proteins are central to the regulation of myofibroblast contraction (GO:1904328) based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ACTA2 | Encodes alpha-smooth muscle actin, the main contractile protein in myofibroblasts. | Marker of myofibroblast differentiation; target for knockout to assess contractility. |
| TGFB1 | Master cytokine driving myofibroblast differentiation and contraction. | Knockout or overexpression models to study fibrosis. |
| RhoA | Small GTPase that activates ROCK to promote contractility. | Point mutation models to study GTPase cycling. |
| ROCK1 | Serine/threonine kinase downstream of RhoA that enhances actin-myosin contraction. | Knockout or inhibitor studies to reduce fibrosis. |
| ROCK2 | Isoform of ROCK with distinct roles in myofibroblast contraction. | Conditional knockout to dissect isoform-specific functions. |
| SMAD7 | Inhibitory SMAD that negatively regulates TGF-beta signaling and fibrosis. | Overexpression protects against heart remodeling. |
| COL5A1 | Type V collagen, regulates scar size and mechanical properties after heart injury. | Knockout mice show altered scar and myofibroblast behavior. |
| TRPV4 | Calcium-permeable channel that activates RhoA via RhoGDI1. | Knockout or agonist studies to modulate contraction. |
| RhoGDI1 | Regulates RhoA localization and activity. | Knockdown or knockout to study RhoA cycling. |
| MYH9 | Non-muscle myosin heavy chain involved in contractile force generation. | Mutagenesis to study motor activity. |
| MYL9 | Myosin light chain regulated by calcium/MLCK. | Phospho-mimetic mutations to study contraction. |
| MYLK | Myosin light chain kinase, phosphorylates MLC in response to calcium. | Knockout to reduce contractility. |
| PPP1R12A | Myosin light chain phosphatase regulatory subunit, opposes MLCK. | Knockout to increase contraction. |
| ITGB1 | Integrin beta-1, mediates force transmission to ECM. | Knockout to disrupt mechanical feedback. |
| YAP1 | Mechanosensitive transcriptional co-activator promoting myofibroblast phenotype. | Knockout to test mechanical feedback. |
| WWTR1 | TAZ, paralog of YAP1, involved in mechanotransduction. | Double knockout with YAP1. |
| SMAD2 | TGF-beta effector promoting myofibroblast gene expression. | Knockout to block TGF-beta signaling. |
| SMAD3 | TGF-beta effector with pro-fibrotic roles. | Knockout to reduce fibrosis. |
How Is regulation of myofibroblast contraction Regulated?
The regulation of myofibroblast contraction is controlled by multiple signaling pathways. TGF-beta signaling through SMAD2/3 promotes the expression of contractile genes, while SMAD7 provides negative feedback. RhoA/ROCK signaling is activated by mechanical cues and calcium influx via TRPV4, and is inhibited by RhoGDI1. Calcium/calmodulin-dependent MLCK and MLCP balance myosin light chain phosphorylation to fine-tune contractility. Mechanical feedback from the ECM further modulates these pathways, creating a dynamic regulatory network.
regulation of myofibroblast contraction and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SMAD7 | Pressure-overload heart failure; fibrosis | Fibroblast-specific Smad7 knockout or overexpression mice |
| TRPV4 | Hypertension; vascular remodeling | TRPV4 knockout mice or cell lines |
| COL5A1 | Cardiac scar formation after myocardial infarction | Col5a1 knockout mice |
| ACTA2 | Fibrosis; wound healing | ACTA2 knockout fibroblasts |
| RhoA | Hypertension; fibrosis | RhoA point mutation knock-in cells |
Tissue Fibrosis and Scar Formation
Persistent myofibroblast contraction leads to fibrosis in the heart, skin, lung, and kidney. In myocardial infarction, myofibroblasts produce a stiff scar that impairs heart function, and type V collagen regulates scar size. Pharmacological targeting of myofibroblast contraction is a promising antifibrotic strategy. Smad7 induction in fibroblasts protects against pressure-overload heart remodeling, demonstrating the therapeutic potential of modulating this process.
Hypertension and Vascular Remodeling
RhoA activation in vascular smooth muscle and myofibroblasts contributes to hypertension. Inactivation of RhoA through the TRPV4-RhoA-RhoGDI1 axis reduces blood pressure in hypertension models. Vascular smooth muscle cell phenotypic switching to a myofibroblast-like state is involved in atherosclerosis. Thus, regulation of myofibroblast contraction is directly relevant to cardiovascular disease.
Skin Wound Healing and Pathological Scarring
In skin, myofibroblast contraction is essential for wound closure, but excessive contraction leads to hypertrophic scars and keloids. Dermal extracellular matrix molecules regulate skin development and wound regeneration. Dysregulated myofibroblast contraction contributes to pathological scarring, making it a target for therapies.
From regulation of myofibroblast contraction-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ACTA2 reduce myofibroblast contraction? | ACTA2 knockout cell line (CRISPR KO) |
| Does a RhoA activating mutation increase contractility? | RhoA point mutation knock-in (e.g., G14V) |
| Can SMAD7 overexpression protect against fibrosis? | SMAD7 overexpression in fibroblasts |
| What is the role of TRPV4 calcium influx in contraction? | TRPV4 knockout or tagged knock-in for live imaging |
| How does type V collagen regulate scar size? | COL5A1 knockout mouse model |
| Does ROCK inhibition reduce myofibroblast contraction? | ROCK1/2 knockout or pharmacological inhibition |
How to Study the regulation of myofibroblast contraction Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Traction force microscopy | Forces exerted by cells on ECM | Quantify myofibroblast contractility |
| Live-cell imaging | Dynamics of actin stress fibers | Visualize contraction in real time |
| RNA-seq | Transcriptional changes | Identify genes regulated during contraction |
| CRISPR screen | Gene function on a genome-wide scale | Discover novel regulators of contraction |
| Phosphoproteomics | Phosphorylation events | Map signaling pathways |
| Collagen gel contraction assay | Macroscopic contraction of collagen gels | Assess myofibroblast contractile function |
| Calcium imaging | Intracellular calcium levels | Study TRPV4-mediated calcium influx |
| Western blot | Protein expression and phosphorylation | Validate ACTA2 and MLC phosphorylation |
Live-Cell Imaging and Traction Force Microscopy
Live-cell imaging of fluorescently tagged ACTA2 or myosin allows real-time visualization of stress fiber dynamics and contraction. Traction force microscopy measures the forces exerted by myofibroblasts on the ECM, providing quantitative assessment of contractility. These methods are essential for studying GO:1904328 at the cellular level.
RNA Sequencing and Transcriptomics
RNA-seq can identify genes differentially expressed during myofibroblast differentiation and contraction, revealing novel regulators. Single-cell RNA-seq can dissect heterogeneity among myofibroblast populations in fibrotic tissues. These approaches help annotate genes to GO:1904328.
CRISPR Screening and Functional Genomics
Genome-wide CRISPR knockout or activation screens can identify genes that regulate myofibroblast contraction. For example, screening for regulators of ACTA2 expression or collagen gel contraction can uncover new therapeutic targets. These screens are powerful for unbiased discovery.
Proteomics and Phosphoproteomics
Mass spectrometry-based proteomics can quantify changes in contractile proteins and their post-translational modifications, such as myosin light chain phosphorylation. Phosphoproteomics can reveal signaling nodes downstream of RhoA/ROCK. These methods provide mechanistic insight into regulation.
How CRISPR Can Be Used to Study GO:1904328 regulation of myofibroblast contraction
Knockout
CRISPR knockout of genes such as ACTA2, RhoA, or TRPV4 in fibroblasts or myofibroblast cell lines can determine their necessity for contraction. For example, ACTA2 knockout reduces stress fiber formation and contractile force. RhoA knockout abolishes ROCK activation and contraction. These models are essential for causal inference in GO:1904328 research.
Point Mutation
Point mutations can be introduced to mimic activating or inactivating states. For instance, a RhoA G14V mutation locks RhoA in an active state, increasing contractility, while a T19N mutation renders it inactive. Such models help dissect the GTPase cycle in myofibroblast contraction.
Knock-in
Knock-in of fluorescent tags (e.g., GFP) into endogenous loci such as ACTA2 or MYH9 allows live-cell imaging of contractile machinery without overexpression artifacts. Knock-in of reporter genes can also monitor signaling pathway activity.
Overexpression
Overexpression of SMAD7, an inhibitory SMAD, in fibroblasts protects against fibrosis by blocking TGF-beta signaling. Overexpression of constitutively active RhoA or ROCK can enhance contraction, providing gain-of-function models. These approaches complement loss-of-function studies.
How EDITGENE Supports regulation of myofibroblast contraction Research
Researchers studying regulation of myofibroblast contraction-related genes often need to determine whether a candidate gene is causally involved in the process, and CRISPR-based cell models provide a robust way to test this. EDITGENE offers a comprehensive suite of services to support such investigations, from knockout to overexpression and library screening.
Contact EDITGENE today to design your custom CRISPR model for regulation of myofibroblast contraction research.
Frequently Asked Questions About regulation of myofibroblast contraction
What is GO:1904328?
GO:1904328 is the Gene Ontology term for regulation of myofibroblast contraction, defined as any process that modulates the frequency, rate or extent of myofibroblast contraction.
What genes are involved in regulation of myofibroblast contraction?
Key genes include ACTA2, TGFB1, RhoA, ROCK1/2, SMAD7, COL5A1, and TRPV4, among others.
How is myofibroblast contraction regulated?
It is regulated by mechanical cues, TGF-beta signaling, calcium signaling, and RhoA/ROCK pathway activity.
What diseases are associated with myofibroblast contraction?
Fibrosis, heart failure, hypertension, and pathological scarring are associated with dysregulated myofibroblast contraction.
What methods are used to study regulation of myofibroblast contraction?
Methods include traction force microscopy, live-cell imaging, RNA-seq, CRISPR screens, and phosphoproteomics.
Can CRISPR be used to study myofibroblast contraction?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect gene function in this process.
What is the role of RhoA in myofibroblast contraction?
RhoA activates ROCK, which promotes actin-myosin contraction and stress fiber formation.
How does TGF-beta regulate myofibroblast contraction?
TGF-beta signaling through SMAD2/3 induces contractile gene expression, while SMAD7 inhibits this pathway.
What is the role of calcium in myofibroblast contraction?
Calcium influx via TRPV4 activates RhoA and MLCK, leading to increased contractility.
How can I model regulation of myofibroblast contraction in the lab?
You can use CRISPR-edited cell lines, primary fibroblasts, or animal models with traction force microscopy and molecular assays.
Conclusion
GO:1904328, regulation of myofibroblast contraction, is a critical biological process that integrates mechanical, chemical, and genetic signals to control contractile force in myofibroblasts. Dysregulation of this process underlies fibrosis, heart failure, and hypertension, making it a prime therapeutic target. Advances in CRISPR-based models and functional genomics are accelerating the discovery of novel regulators and drug candidates. EDITGENE's services support these efforts by providing custom cell models and screening platforms.
References
- 1. Hinz B et al.. 2019. Mechanical regulation of myofibroblast phenoconversion and collagen contraction.. Exp Cell Res 379(1):119-128 PMID: 30910400
- 2. He ZQ et al.. 2022. Pharmacological regulation of tissue fibrosis by targeting the mechanical contraction of myofibroblasts.. Fundam Res 2(1):37-47 PMID: 38933917
- 3. Huang J et al.. 2022. Dermal extracellular matrix molecules in skin development, homeostasis, wound regeneration and diseases.. Semin Cell Dev Biol 128:137-144 PMID: 35339360
- 4. Humeres C et al.. 2024. Fibroblast Smad7 Induction Protects the Remodeling Pressure-Overloaded Heart.. Circ Res 135(3):453-469 PMID: 38899461
- 5. Wang J et al.. 2025. Inactivation of RhoA for Hypertension Treatment Through the TRPV4-RhoA-RhoGDI1 Axis.. Circulation 152(8):519-536 PMID: 40518994
- 6. Follonier Castella L et al.. 2010. Regulation of myofibroblast activities: calcium pulls some strings behind the scene.. Exp Cell Res 316(15):2390-401 PMID: 20451515
- 7. Yokota T et al.. 2020. Type V Collagen in Scar Tissue Regulates the Size of Scar after Heart Injury.. Cell 182(3):545-562.e23 PMID: 32621799
- 8. Zhang F et al.. 2021. An update on the phenotypic switching of vascular smooth muscle cells in the pathogenesis of atherosclerosis.. Cell Mol Life Sci 79(1):6 PMID: 34936041
